The GLP-1 coverage Massachusetts did not enact
The most specific thing the Commonwealth has published about GLP-1 coverage for its own employees is a section that never became law. It was filed as Amendment #7 to a supplemental budget, it named the drugs, the indications and the money, and it is not in the act that passed. Meanwhile the state's own health policy agency had already measured how many people are buying these drugs here, and said plainly that its numbers cannot see anyone paying cash.
What changed, and what the document says
What was proposed
ContextCoverage for state employees and retirees, tied to the FDA label rather than to a plan's own definition of obesity.
“Any coverage offered by the commission to an active or retired employee of the commonwealth insured under the group insurance commission shall provide coverage for glucagon-like peptide-1 receptor agonist medications (GLP-1s) that have been approved by the United States Food and Drug Administration for: (i) treatment of diabetes; (ii) chronic weight management or obesity; or (iii) any other indication for which such medication has received FDA approval.”
The 194th General Court of the Commonwealth of Massachusetts — June 30, 2026
The clause aimed at the fine print
ContextIt would have blocked both of the moves a plan normally makes — a tighter necessity test, and a change made partway through a plan year.
“Such coverage shall not be restricted to circumstances of “medical necessity” narrower than the FDA-approved indications, nor shall coverage be eliminated or reduced by mid-year plan design changes.”
The 194th General Court of the Commonwealth of Massachusetts — June 30, 2026
What it was costed at
ContextA single appropriation, attached to the section it would have paid for, with an expiry date on it.
“Notwithstanding any general or special law to the contrary, the sum of $27,500,000 is hereby appropriated to the Group Insurance Commission for the purpose of implementing section 17T of chapter 32A of the General Laws.”
The 194th General Court of the Commonwealth of Massachusetts — June 30, 2026
What was signed instead
Not coveredThe budget it was filed to became law three sections long, and none of those sections mentions the commission or any of these drugs.
“Approved, September 22, 2025.”
The 194th General Court of the Commonwealth of Massachusetts — Session Laws — Approved, September 22, 2025
How many people this is about
ContextThe Commonwealth's own health policy agency measured the share of commercially insured residents on one of these drugs, and it had multiplied sevenfold in five years.
“In the first nine months of 2023, 3.2% of Massachusetts commercial members were prescribed a GLP-1 drug, a seven-fold increase from 2018, when 0.5% of members were prescribed one of these medications.”
Massachusetts Health Policy Commission — ISSUE 27: AUGUST 2024
What it already costs privately
Conditions applyThe spending figure behind the debate, doubling year on year on the commercial side alone.
“In 2023, total commercial spending (gross) on GLP-1 drugs in Massachusetts is projected to surpass $270 million, more than double the spending in 2022, which was nearly $125 million.”
Massachusetts Health Policy Commission — ISSUE 27: AUGUST 2024
The people the numbers cannot see
ContextThe agency says outright that anyone buying these drugs with their own money is missing from its count, and names online sellers as one of the reasons.
“One important limitation of this analysis is that it only identifies GLP-1 medications billed to commercial insurance and, consequently, cannot account for people who are paying for GLP-1 drugs entirely out of pocket, whether prescribed by traditional providers or through direct to consumer online telehealth providers.”
Massachusetts Health Policy Commission — ISSUE 27: AUGUST 2024
What the state didn't publish
The enacted law contains no trace of the GLP-1 section or its appropriation. Nothing about these drugs survived into Chapter 33 of the Acts of 2025 in any form.
We looked at 3 documents to say that — the whole enacted text of Chapter 33 of the Acts of 2025 — all three of its sections and both of its appropriation line items, 10,094 characters, read end to end.
The identical scan, in the same run, found hospital 37 times, Medicaid 6 times, trust fund twice and 10 dollar amounts in the enacted text — the ruler reads this act. Against that same text, GLP, glucagon, semaglutide, tirzepatide, liraglutide, Wegovy, Zepbound, Ozempic, Saxenda, obesity, weight and the phrase group insurance each returned zero.
Checked September 2026 against Chapter 33 of the Acts of 2025 — An Act making appropriations for fiscal year 2025 to provide for supplementing certain existing appropriations and for certain other activities and projects, The 194th General Court of the Commonwealth of Massachusetts — Session Laws.
Which of these companies serve Massachusetts?
Of the 257 companies we grade, 25 publish a list of the states they are licensed in. We checked 229 more and found no such list on any page we read; 3 we have not checked either way.
18 of those lists name Massachusetts: Gala Health, Care Bare Rx, Vita Bella, TelePeptide, Levity, Wisp, WePeptideRx, Ways2Well, TeleClinic, Tyde Wellness, Willow, VevaRx, Trimi, Enhance MD, HumeCare+, Rx.com, Mojoon and Peak Wellness. That is a licensure claim each company makes about itself, not something we checked with a state board.
A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.
Sources
Each document below was fetched and read on the date shown beside it, which is the date printed on the document — not always the date in its web address. All of them were read in September 2026, the same session as the rest of this page.
- Amendment #7 to H4530 — Coverage for GLP-1's for GIC Employees — The 194th General Court of the Commonwealth of Massachusetts. the only date printed anywhere on the amendment — the day its own appropriation would have run out; the text carries no filing or action date: June 30, 2026.
- Chapter 33 of the Acts of 2025 — An Act making appropriations for fiscal year 2025 to provide for supplementing certain existing appropriations and for certain other activities and projects — The 194th General Court of the Commonwealth of Massachusetts — Session Laws. the approval line printed as the last line of the enacted text: Approved, September 22, 2025.
- HPC DataPoints Issue 27: Blockbuster GLP-1 Weight-Loss Drugs in Massachusetts — Massachusetts Health Policy Commission. the issue line printed at the top of the brief's first page: ISSUE 27: AUGUST 2024.
Nothing on this page is medical advice, and nobody here is a clinician. Coverage rules change; check the linked document before you rely on it.
If you're paying cash instead
None of the above changes what a telehealth seller charges you. None of the 3 rows below carries both a medication price and a monthly fee we could capture, so no figure here is a sum. Each cell says what its number covers and what we could not confirm, and every number was read on the seller's own page.
PlushCare, Calibrate Health and Willow pay us nothing — none of the 3 below does. The buttons run through our own redirect so we can count the click, and counting is all they do.
| Grade | Provider | What a month actually costs | The one thing that matters here | Go to the provider |
|---|---|---|---|---|
| BMinor gap | PlushCare | No month-to-month medication price we could capture, so there is no monthly total to show.What they do bill every month: $19.99 a month for membership.Charged per visit rather than every month, so it is not in the figure above: $129 for visit, no insurance.The review says what else we found. | Prints both halves of its own price in one panel — $19.99 a month for membership and $129 for a first visit without insurance — and says medication is not included, which is the honest version of the insurance route the amendment was arguing about. | See its prices at PlushCare (opens in a new tab)Pays us nothing |
| CCaveat | Calibrate Health | No month-to-month medication price we could capture, so there is no monthly total to show.What they do bill every month: $199 a month for membership.The review says what else we found. | The closest commercial thing to what the amendment would have built: $199 a month for three months minimum, and it does not sell you the drug at all — it works your coverage for it. | See its prices at Calibrate Health (opens in a new tab)Pays us nothing |
| CCaveat | Willow | $299a month, medication onlycompounded semaglutide injectionMedication only. We captured no separate monthly charge on the pages we read, which is what we found rather than proof that nothing else is billed.Printed on the product page with no asterisk and no dose qualifier. The comparison page and the terms both add one.The lowest of the 4 medication prices we captured here | One clean per-month figure on each product page, $299 for compounded semaglutide whether injected or not, and five named partner pharmacies in its terms with street addresses. | See its prices at Willow (opens in a new tab)Pays us nothing |
Our grading method and how we verify a price explain what those letters mean and where these figures came from.